Publications by authors named "Valentina Summa"

Claim this Profile
T
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries.
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa

Ann Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.
Massimo Breccia, Simone Celant, Francesca Palandri, Francesco Passamonti, Pier Paolo Olimpieri, Valentina Summa

Br J Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò

Hemasphere· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, Carlo Tascini, Simone Celant, Valentina Summa

Lancet Reg Health Eur· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Gian Matteo Rigolin, Pier Paolo Olimpieri, Valentina Summa, Simone Celant, Lydia Scarfò

Blood Cancer J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, Odoardo Maria Olimpieri, Fabrizio Pane, Valentina Summa

Ann Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, Odoardo Olimpieri, Fabrizio Pane, Valentina Summa

Br J Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis.
Giovanni Palladini, Simone Celant, Paolo Milani, Valentina Summa, Giovanni Affronti

Leuk Lymphoma· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, Odoardo M Olimpieri, Fabrizio Pane, Valentina Summa

Ann Hematol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Massimo Breccia, Pier Paolo Olimpieri, Odoardo Olimpieri, Fabrizio Pane, Alessandra Iurlo, Valentina Summa

Cancer Med· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapartum test for detection of Group B Streptococcus colonization during labor.
Elena Picchiassi, Giuliana Coata, Giulia Babucci, Irene Giardina, Valentina Summa

J Matern Fetal Neonatal Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.
Iole Cordone, Serena Masi, Valentina Summa, Mariantonia Carosi, Antonello Vidiri

Breast Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience.
Francesco Marchesi, Serena Masi, Valentina Summa, Svitlana Gumenyuk, Roberta Merola

Br J Haematol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Iole Cordone, Francesco Marchesi, Serena Masi, Valentina Summa, Francesco Pisani

J Exp Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukemia developing in patients with autoimmune diseases.
Safaa M Ramadan, Tamer M Fouad, Valentina Summa, Syed Kh Hasan, Francesco Lo-Coco

Haematologica· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis